de BlackRock Ligand Pharmaceuticals LGND Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 980 M | Comprar |
3,100,996
+139,073
| +5% | +USD 32.8 M | 0.01% | 788 |
|
|
2026
Q1 | USD 591 M | Comprar |
2,961,923
+21,692
| +0.7% | +USD 4.29 M | 0.01% | 978 |
|
|
2025
Q4 | USD 556 M | Comprar |
2,940,231
+55,704
| +2% | +USD 10.7 M | 0.01% | 1023 |
|
|
2025
Q3 | USD 511 M | Vender |
2,884,527
-29,214
| -1% | -USD 4.34 M | 0.01% | 1071 |
|
|
2025
Q2 | USD 331 M | Vender |
2,913,741
-6,494
| -0.2% | -USD 694 k | 0.01% | 1303 |
|
|
2025
Q1 | USD 307 M | Vender |
2,920,235
-25,849
| -0.9% | -USD 2.92 M | 0.01% | 1329 |
|
|
2024
Q4 | USD 316 M | Vender |
2,946,084
-53,548
| -2% | -USD 6.05 M | 0.01% | 1397 |
|
|
2024
Q3 | USD 300 M | Comprar |
2,999,632
+128,136
| +4% | +USD 12.9 M | 0.01% | 1417 |
|
|
2024
Q2 | USD 242 M | Comprar |
2,871,496
+3,226
| +0.1% | +USD 257 k | 0.01% | 1497 |
|
|
2024
Q1 | USD 210 M | Vender |
2,868,270
-94,044
| -3% | -USD 6.93 M | ﹤0.01% | 1611 |
|
|
2023
Q4 | USD 212 M | Comprar |
2,962,314
+121,230
| +4% | +USD 7.15 M | 0.01% | 1617 |
|
|
2023
Q3 | USD 170 M | Vender |
2,841,084
-65,075
| -2% | -USD 4.28 M | ﹤0.01% | 1649 |
|
|
2023
Q2 | USD 210 M | Comprar |
2,906,159
+67,497
| +2% | +USD 5.06 M | 0.01% | 1542 |
|
|
2023
Q1 | USD 209 M | Comprar |
2,838,662
+48,898
| +2% | +USD 3.48 M | 0.01% | 1502 |
|
|
2022
Q4 | USD 186 M | Vender |
2,789,764
-1,483,222
| -35% | -USD 96.4 M | 0.01% | 1590 |
|
|
2022
Q3 | USD 230 M | Vender |
4,272,986
-62,884
| -1% | -USD 3.7 M | 0.01% | 1365 |
|
|
2022
Q2 | USD 241 M | Vender |
4,335,870
-45,621
| -1% | -USD 2.59 M | 0.01% | 1383 |
|
|
2022
Q1 | USD 307 M | Vender |
4,381,491
-15,230
| -0.3% | -USD 1.11 M | 0.01% | 1342 |
|
|
2021
Q4 | USD 424 M | Comprar |
4,396,721
+18,617
| +0.4% | +USD 1.72 M | 0.01% | 1162 |
|
|
2021
Q3 | USD 381 M | Comprar |
4,378,104
+1,100,966
| +34% | +USD 85.2 M | 0.01% | 1210 |
|
|
2021
Q2 | USD 268 M | Vender |
3,277,138
-131,454
| -4% | -USD 10.9 M | 0.01% | 1551 |
|
|
2021
Q1 | USD 324 M | Comprar |
3,408,592
+257,100
| +8% | +USD 24.3 M | 0.01% | 1367 |
|
|
2020
Q4 | USD 196 M | Vender |
3,151,492
-272,692
| -8% | -USD 15.5 M | 0.01% | 1636 |
|
|
2020
Q3 | USD 204 M | Comprar |
3,424,184
+13,553
| +0.4% | +USD 925 k | 0.01% | 1375 |
|
|
2020
Q2 | USD 238 M | Vender |
3,410,631
-129,652
| -4% | -USD 8.22 M | 0.01% | 1236 |
|
|
2020
Q1 | USD 161 M | Vender |
3,540,283
-283,125
| -7% | -USD 16 M | 0.01% | 1325 |
|
|
2019
Q4 | USD 249 M | Vender |
3,823,408
-118,218
| -3% | -USD 7.9 M | 0.01% | 1318 |
|
|
2019
Q3 | USD 245 M | Vender |
3,941,626
-64,119
| -2% | -USD 4.03 M | 0.01% | 1256 |
|
|
2019
Q2 | USD 285 M | Vender |
4,005,745
-385,281
| -9% | -USD 28.4 M | 0.01% | 1159 |
|
|
2019
Q1 | USD 344 M | Vender |
4,391,026
-36,237
| -0.8% | -USD 2.75 M | 0.02% | 1009 |
|
|
2018
Q4 | USD 375 M | Vender |
4,427,263
-937,026
| -17% | -USD 100 M | 0.02% | 825 |
|
|
2018
Q3 | USD 919 M | Comprar |
5,364,289
+130,536
| +2% | +USD 19.7 M | 0.04% | 454 |
|
|
2018
Q2 | USD 676 M | Comprar |
5,233,753
+402,585
| +8% | +USD 44.9 M | 0.03% | 556 |
|
|
2018
Q1 | USD 498 M | Comprar |
4,831,168
+27,041
| +0.6% | +USD 2.67 M | 0.02% | 708 |
|
|
2017
Q4 | USD 410 M | Comprar |
4,804,127
+82,168
| +2% | +USD 7.12 M | 0.02% | 825 |
|
|
2017
Q3 | USD 401 M | Comprar |
4,721,959
+419,699
| +10% | +USD 33.2 M | 0.02% | 801 |
|
|
2017
Q2 | USD 326 M | Comprar |
4,302,260
+110,426
| +3% | +USD 7.72 M | 0.02% | 926 |
|
|
2017
Q1 | USD 277 M | Comprar |
4,191,834
+4,189,319
| +166,573% | +USD 276 M | 0.02% | 1036 |
|
|
2016
Q4 | USD 159 k | Vender |
2,515
-576
| -19% | -USD 36.3 k | ﹤0.01% | 2286 |
|
|
2016
Q3 | USD 197 k | Vender |
3,091
-4,603
| -60% | -USD 338 k | ﹤0.01% | 2162 |
|
|
2016
Q2 | USD 572 k | Comprar |
7,694
+5,480
| +248% | +USD 407 k | ﹤0.01% | 1623 |
|
|
2016
Q1 | USD 147 k | Comprar |
2,214
+1,379
| +165% | +USD 83.8 k | ﹤0.01% | 1823 |
|
|
2015
Q4 | USD 56 k | Vender |
835
-255
| -23% | -USD 15.7 k | ﹤0.01% | 1988 |
|
|
2015
Q3 | USD 59 k | Vender |
1,090
-9,604
| -90% | -USD 583 k | ﹤0.01% | 1842 |
|
|
2015
Q2 | USD 673 k | Comprar |
10,694
+9,607
| +884% | +USD 524 k | ﹤0.01% | 1477 |
|
|
2015
Q1 | USD 52 k | Vender |
1,087
-1,055
| -49% | -USD 40.4 k | ﹤0.01% | 1936 |
|
|
2014
Q4 | USD 71 k | Comprar |
2,142
+1,267
| +145% | +USD 41.2 k | ﹤0.01% | 1825 |
|
|
2014
Q3 | USD 26 k | Mantener |
875
| – | – | ﹤0.01% | 2200 |
|
|
2014
Q2 | USD 34 k | Vender |
875
-133
| -13% | -USD 5.4 k | ﹤0.01% | 2107 |
|
|
2014
Q1 | USD 43 k | Comprar |
1,008
+304
| +43% | +USD 12.7 k | ﹤0.01% | 1978 |
|
|
2013
Q4 | USD 23 k | Vender |
704
-46
| -6% | -USD 1.5 k | ﹤0.01% | 2293 |
|
|
2013
Q3 | USD 20 k | Mantener |
750
| – | – | ﹤0.01% | 2276 |
|
|
2013
Q2 | USD 18 k | Comprar |
+750
| Nuevas | +USD 13.5 k | ﹤0.01% | 2350 |
|
Otros fondos que tienen LGND en su cartera
Posición de BlackRock en LGND: resumen de T2 2026
BlackRock aumentó su participación en Ligand Pharmaceuticals (LGND) en 4.7% durante T2 2026, al comprar aproximadamente USD 32.8 M y elevar la posición a 3,100,996 acciones con un valor de USD 980 M. La posición representa 0.01% de la cartera y ocupa el puesto #788.
BlackRock reportó por primera vez una posición en LGND en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 418 fondos que sigue Wall St. Rank mantienen una posición en LGND.
- Al cierre de T2 2026, BlackRock tenía 3,100,996 acciones de Ligand Pharmaceuticals con un valor de USD 980 M.
- BlackRock compró 139,073 acciones de Ligand Pharmaceuticals en T2 2026, por un monto estimado de USD 32.8 M.
- Ligand Pharmaceuticals representó 0.01% de la cartera de BlackRock en T2 2026 y fue su posición número 788.
- BlackRock reportó por primera vez una posición en Ligand Pharmaceuticals en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 418 fondos que sigue Wall St. Rank tenían Ligand Pharmaceuticals en cartera.
Según el Informe 13F de BlackRock correspondiente a T2 2026, presentado el 7 ago 2026.